

Special Issue

Emerging and Reemerging Viral Infection, Immunopathogenesis and Diagnosis of Viral Infection, and Development of the Novel Antiviral Strategies

Message from the Guest Editors

We are launching Special Issue on Emerging and re-emerging viral infections, immunopathogenesis and diagnosis of viral infections, and the development of novel antiviral strategies. In recent years, we have seen many emerging viruses, such as SARS-CoV-2, and re-emerging viruses, such as the monkeypox virus. Many virus outbreaks are ongoing in different parts of the world, causing morbidity and mortality: the COVID-19 pandemic, the monkeypox outbreak in nonendemic countries, the Dengue outbreak in Southeast Asia, CCHF, and the West Nile virus in Europe and America. Langya virus was detected in China, H1N1 and Nipha virus in India, a measles outbreak in Zimbabwe, and many more. Viral infection in any part of the world is a threat to global health and has the potential to cause epidemics and pandemics. Therefore, the diagnosis, detection, and management of viruses should be performed at their origin. With these issues in mind, in this Special Issue, we welcome original articles, review articles, perspectives, and interesting case series of emerging and reemerging viruses.

Guest Editors

Dr. Ranjit Sah

Prof. Dr. Alfonso J. Rodriguez-Morales

Dr. Harapan Harapan

Deadline for manuscript submissions

closed (30 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/144940

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).